Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)−associated …

… mostly on CD4 positive T lymphocytes, has an inhibitory effect on T lymphocytes by binding
… on T lymphocytes, for binding to CD80 and CD86. If T lymphocytes are activated via the T …

… Antibodies blocking immune checkpoints that function as negative regulators of T-cell function,
cytotoxic T-lymphocyte–associated antigen 4 (CTLA4), programmed death 1 (PD-1), and …

Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over
150,000 patients in the United States suffer from breathlessness and diminished quality of …

Background The 18-month efficacy of a single course of rituximab as compared with conventional
immunosuppression with cyclophosphamide followed by azathioprine in patients with …

Objective This study was conducted to evaluate the efficacy and safety of repeated and
prolonged B cell depletion with rituximab (RTX) for the maintenance of long‐term remission in …

… Dr Peikert was supported by NIH training grant T32-HL07897. The WGET trial was
supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH N01-…

… Peikert was supported by NIH training grant T32-HL07897. The WGET was supported by
the NIAMS, NIH (grant N01-AR92240) and the Office of Orphan Products, US Food and Drug …

… B7 homolog 1 (B7-H1; also known as programmed cell death 1 ligand 1) is a negative
costimulatory molecule that is constitutively expressed on macrophage-lineage cells and inhibits T…

… T lymphocytes predominately infiltrated into fibrotic areas and were found in close proximity
to smooth muscle actin-positive fibroblasts rather than in the periphery of the lesions (Figure …